Arginase 1 Deficiency Foundation Files Petition Urging Aeglea Biotherapeutics to Reinstate Life-Saving Drug Following Abrupt Withdrawal to Clinical Trial Patients in the United States

Arginase 1 Deficiency Foundation Files Petition Urging Aeglea Biotherapeutics to Reinstate Life-Saving Drug Following Abrupt Withdrawal to Clinical Trial Patients in the United States Seattle, Washington, April 21, 2023: The Arginase 1 Deficiency Foundation, a leading advocacy group for individuals and families impacted by the debilitating rare metabolic disease, has launched a petition demanding that […]

Caregivers’ Experiences Survey

We’re proud to partner with the Child Neurology Foundation to conduct a survey to understand caregivers’ experiences on their journey in child neurology. Results will be shared with advocates and health care providers, so they are better able serve families. Caregivers of children with neurologic conditions can complete the brief survey thru April 1st at: www.surveymonkey.com/r/2022CNFCaregiverAssessment

KOL and Patient Caregiver Webinar on Arginase 1 Deficiency

PEGZILARGINASE Trial Discussion. Amazing presentation with Dr. Diaz, Dr. Burton and our own Tanja Brandt discuss Arginase 1 Deficiency, the Phase 2 and Phase 3 trial. Tanja discusses the day to day care taking of an individual with Arg1D. Great information on Arginase Deficiency 1 and the future of treating with the enzyme. This link […]

Phase 3 PEACE study achieved its primary endpoint

I am excited to share with you that today we announced our Phase 3 PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) study achieved its primary endpoint with a statistically significant reduction in plasma arginine levels. Pronounced and sustained plasma arginine reduction was accompanied by a positive trend in the Gross Motor Function Measure Part E (GMFM-E), a key clinical assessment of patient mobility. Based on these […]

Redacted FDA Listening session

On June 10, 2021, a group of patients and families affected by Arginase 1 Deficiency (ARG1-D) participated in a one-hour virtual listening session with officials from the Food and Drug Administration (FDA). The session enabled those with ARG1-D and their caregivers to  share their experiences, perspectives, needs, goals with officials from across the agency. During the […]

Aeglea BioTherapeutics & Immedica Commercialization Agreement

Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East Published: Mar 22, 2021 Original Story HERE AUSTIN, Texas and STOCKHOLM, March 22, 2021 /PRNewswire/ — Aeglea Biotherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative […]

Aeglea BioTherapeutics Launches THINK ARGININE™

Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency 05/06/2021 Original Story HERE Includes Sponsored Diagnostic Testing and Services for Patients with Suspected Arginase 1 Deficiency AUSTIN, Texas, May 6, 2021 /PRNewswire/ — Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human […]

Skip to content